<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01824953</url>
  </required_header>
  <id_info>
    <org_study_id>KUH1010393</org_study_id>
    <secondary_id>1010393</secondary_id>
    <secondary_id>KUH 1010393</secondary_id>
    <nct_id>NCT01824953</nct_id>
  </id_info>
  <brief_title>Long-term Follow-up Prognosis of Atrophic Gastritis After 3 Years</brief_title>
  <official_title>Significance of Helicobacter Pylori Infection and Pepsinogen Levels on the Prognosis of Atrophic Gastritis - Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Konkuk University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Konkuk University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Serum pepsinogen (PG) levels are considered reliable markers for progression of atrophic&#xD;
      gastritis with a stepwise reduction in the serum PG I level or PG I/II ratio. A combination&#xD;
      of serum PG levels and Helicobacter pylori serology are used as a biomarker strategy for&#xD;
      detection of individuals at increased risk of gastric neoplasm based on Correa's hypothesis.&#xD;
      The investigators aimed to uncover whether this combination method could predict the risk of&#xD;
      gastric neoplasms and the progression of chronic atrophic gastritis after 3 years. All the&#xD;
      participants will be followed for an expected average of 3 years.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      According to the Correa's hypothesis, the combination method using serum pepsinogen levels&#xD;
      and serum Helicobacter pylori antibody would predict the risk and cell type of gastric&#xD;
      neoplasm. However, in endemic regions of H. pylori infection such as in East Asian countries&#xD;
      (Korea, Japan, and China), most of the aged population are have current or had past H. pylori&#xD;
      infection. Therefore, in this study, we are going to uncover whether the risk of gastric&#xD;
      neoplasm is significantly higher in the atrophy(+)/H. pylori(-) group followed by&#xD;
      atrophy(+)/H. pylori(+), atrophy(-)/H. pylori(+), and atrophy(-)/H. pylori(-) groups. In&#xD;
      addition, we are going to investigate whether those slow-growing gastric neoplasms such as&#xD;
      differentiated gastric cancers with Lauren's intestinal type and gastric adenoma are more&#xD;
      commonly developed in atrophy group following the Correa's hypothesis, whereas rapid-growing&#xD;
      gastric neoplasms such as poorly-cohesive carcinoma or undifferentiated gastric cancers with&#xD;
      Lauren's diffuse type are more commonly developed in the subjects without atrophy. Taken as a&#xD;
      whole, our study result will provide an evidence whether this biomarker strategy are useful&#xD;
      for the detection of individuals at increased risk of gastric neoplasm.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>Newly developed gastric neoplasm</measure>
    <time_frame>December 31, 2013</time_frame>
    <description>Newly developed gastric neoplasm</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Degree of gastric atrophy</measure>
    <time_frame>December 31, 2013</time_frame>
    <description>Degree of gastric atrophy measured by serum pepsinogen I and II levels</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Helicobacter pylori</measure>
    <time_frame>December 31, 2013</time_frame>
    <description>Presence of Helicobacter pylori infection</description>
  </other_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">3328</enrollment>
  <condition>Gastric Neoplasm</condition>
  <condition>Gastric Cancer</condition>
  <condition>Gastric Adenoma</condition>
  <condition>Gastric Atrophy</condition>
  <condition>Intestinal Metaplasia</condition>
  <arm_group>
    <arm_group_label>atrophy-/Hp- group</arm_group_label>
    <description>Subjects without Helicobacter pylori infection and without atrophy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>atrophy-/Hp+</arm_group_label>
    <description>Subjects with Helicobacter pylori infection and without atrophy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>atrophy+/Hp+</arm_group_label>
    <description>Subjects with Helicobacter pylori infection and with atrophy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>atrophy+/Hp-</arm_group_label>
    <description>Subjects without Helicobacter pylori infection and with atrophy</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum for Helicobacter pylori antibody and pepsinogen levels Gastric biopsy for the diagnosis&#xD;
      of intestinal metaplasia, atrophy, inflammatory cells, Helicobacter pylori, and the presence&#xD;
      of gastric neoplasm if any.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Asymptomatic Korean adults who underwent serum PG tests, H. pylori serology, and upper&#xD;
        gastrointestinal endoscopy on the same day at our center.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Korean adults older than 18 year-old&#xD;
&#xD;
          -  Subjects who agreed on serum pepsinogen tests, H. pylori serology, and upper&#xD;
             gastrointestinal endoscopy on the same day&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who had past history of gastric surgery&#xD;
&#xD;
          -  Abnormal endoscopic or laboratory finding that require further treatment&#xD;
&#xD;
          -  Any evidence of malignancy other than gastric neoplasm&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sun-Young Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Internal Medicine, Konkuk Universtiy Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Konkuk University Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>143-729</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Konkuk University Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <study_first_submitted>March 28, 2013</study_first_submitted>
  <study_first_submitted_qc>April 2, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 5, 2013</study_first_posted>
  <last_update_submitted>August 15, 2013</last_update_submitted>
  <last_update_submitted_qc>August 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 16, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Konkuk University Medical Center</investigator_affiliation>
    <investigator_full_name>Sun-Young Lee</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <keyword>Gastric atrophy</keyword>
  <keyword>Helicobacter pylori</keyword>
  <keyword>Pepsinogen</keyword>
  <keyword>Gastric cancer</keyword>
  <keyword>Gastric adenoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Adenoma</mesh_term>
    <mesh_term>Gastritis</mesh_term>
    <mesh_term>Gastritis, Atrophic</mesh_term>
    <mesh_term>Atrophy</mesh_term>
    <mesh_term>Metaplasia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

